JAMA Surg:依前列醇吸入用于预防肺移植后严重/3级原发性移植物功能障碍

2021-11-23 MedSci原创 MedSci原创

吸入依前列醇在预防肺移植后严重/3级原发性移植物功能障碍方面的效果与吸入一氧化氮相当

吸入一氧化氮(iNO)通常用于肺血管舒张和预防肺移植(LT)后的氧化损伤。依前列醇(IEPO)有抗血小板和舒张血管作用,可防止血栓生成,用于严重外周血管性疾病、缺血性心脏病,特发性肺动脉高压(IPAH)、血小板消耗性疾病等,相比于iNO,其更具成本优势。近日研究人员考察了吸入依前列醇对肺移植患者严重/3级原发性移植物功能障碍(PGD-3)风险的影响。

201名单侧或双侧LT患者参与研究,患者在同种异体肺移植再灌注前,在手术室即开始使用iNO或iEPO治疗,并持续到重症监护病房(ICU),直至满足停止标准。研究的主要终点为LT后24、48或72小时 PGD-3事件。次要终点包括机械通气时间、住院时间和ICU住院时间、急性肾损伤的发生率和严重程度、术后气管切开术、住院率、30天和90天死亡率。

201名患者中,男性129人(64.2%)。在意向治疗人群中,103人接受iEPO,98人接受iNO。iEPO组中46人出现PGD-3事件(44.7%),而iNO组39人(39.8%),组间PGD-3风险差异为4.9%。组间各个次要终点发生率无显著差异。

iNO vs iEPO组间PGD-3风险差异

研究认为,吸入依前列醇在预防肺移植后严重/3级原发性移植物功能障碍方面的效果与吸入一氧化氮相当

原始出处:

Kamrouz Ghadimi al. Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant A Randomized Clinical Trial. JAMA Surg. November 17, 2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1847009, encodeId=d9f1184e00928, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon May 02 18:18:02 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745389, encodeId=3dc51e45389f1, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 15 05:18:02 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421407, encodeId=efb7142140e51, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu Nov 25 10:18:02 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620773, encodeId=8a1d1620e733e, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Thu Nov 25 10:18:02 CST 2021, time=2021-11-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1847009, encodeId=d9f1184e00928, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon May 02 18:18:02 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745389, encodeId=3dc51e45389f1, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 15 05:18:02 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421407, encodeId=efb7142140e51, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu Nov 25 10:18:02 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620773, encodeId=8a1d1620e733e, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Thu Nov 25 10:18:02 CST 2021, time=2021-11-25, status=1, ipAttribution=)]
    2021-12-15 xuyong535
  3. [GetPortalCommentsPageByObjectIdResponse(id=1847009, encodeId=d9f1184e00928, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon May 02 18:18:02 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745389, encodeId=3dc51e45389f1, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 15 05:18:02 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421407, encodeId=efb7142140e51, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu Nov 25 10:18:02 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620773, encodeId=8a1d1620e733e, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Thu Nov 25 10:18:02 CST 2021, time=2021-11-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1847009, encodeId=d9f1184e00928, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon May 02 18:18:02 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745389, encodeId=3dc51e45389f1, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Wed Dec 15 05:18:02 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421407, encodeId=efb7142140e51, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu Nov 25 10:18:02 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620773, encodeId=8a1d1620e733e, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Thu Nov 25 10:18:02 CST 2021, time=2021-11-25, status=1, ipAttribution=)]

相关资讯

回顾性研究:肺移植后发生静脉血栓栓塞的危险因素有哪些

肺移植后静脉血栓栓塞(VTE)是比较常见的,并与移植后生存恶化相关。那么肺移植后发生静脉血栓栓塞的危险因素有哪些呢?

JHLT:基于体外膜氧合技术,肺动脉高压 患者具有较低的移植率?

肺移植的供体分配会严重影响等待肺移植病人的未来,如何分配才能让更多的人收益?

Dig Dis Sci: 肺移植术后胃轻瘫的危险因素和结果分析

胃轻瘫是最常见的手术后并发症,与糖尿病,病毒感染,风湿病和神经障碍的存在都有关系。胃轻瘫在肺移植后的患者中很常见,患病率为 23-91%。

Eur Respir J:血清中小HDL颗粒水平与死亡或肺移植呈负相关

IPF患者血清中较高的S-HDLPNMR水平与GAP指数以及较低的死亡率或肺移植呈负相关。这些结果支持S-HDLPNMR可能改变IPF患者死亡风险的假设。

J heart Lung Transplant:间质性肺疾病肺移植中供体-受体大小匹配的简化策略

供体-受体尺寸匹配已多次被报道可以改善肺移植(LTx)的预后。然而,在实践中有很大的可变性,最佳的尺寸匹配策略还没有定义。

Lancet Respirat Med:肺内微生物群状况可预测肺移植患者预后!

在慢性肺部疾病中常见呼吸微生物群改变,与肺功能下降有关,还与疾病进展有关。肺移植后呼吸微生物群变化的临床意义,特别是与慢性肺同种异体移植功能障碍(CLAD)的发展有关的临床意义尚不清楚。本研究旨在评估